Germany · Delayed Price · Currency is EUR Alkermes Company Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1987 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 1,800 |
| CEO | Richard Pops |
Contact Details
Address: Connaught House Dublin, D04 C5Y6 Ireland | |
| Phone | 353 1 772 8000 |
| Website | alkermes.com |
Stock Details
| Ticker Symbol | 8AK |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Pops | Chief Executive Officer |
| Joshua Reed | Chief Financial Officer |
| Blair Jackson | Chief Operating Officer |
| Sandra Coombs | Head of Investor Relations |